
AACR: Novartis joins the KRAS clan, eyeing swift move to pha...
Novartis has joined the select cadre of drugmakers developing KRAS inhibitors for cancer, opening its account with phase 1b data on JDQ443 showing efficacy in KRAS-mutated non-small cell lu